Association between the AGTR1 polymorphism +1166A>C and serum levels of high-sensitivity C-reactive protein

Regulatory Peptides

Volumn 152, Issue 1-3, 2009, Pages 28-32

  Suchankova, Petra ^a   Henningsson, Susanne ^a   Olsson, Marie ^a   Baghaei, Fariba ^a   Rosmond, Roland ^a   Holm, Göran ^a   Eriksson, Elias ^a   Ekman, Agneta ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

+1166A>C polymorphism; +1444C>T polymorphism; Angiotensin II (AngII); Angiotensin II type 1 receptor (AGTR1); High sensitivity C reactive protein (hsCRP); Inflammation; Renin angiotensin system (RAS)

Indexed keywords

APELIN RECEPTOR; C REACTIVE PROTEIN;

ADULT; ANTHROPOMETRY; ARTICLE; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; METABOLISM; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; C-REACTIVE PROTEIN; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; POLYMORPHISM, GENETIC; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM;

EID: 57249104699     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2008.11.001     Document Type: Article

References (67)

1. Mendall M.A., Strachan D.P., Butland B.K., Ballam L., Morris J., Sweetnam P.M., and Elwood P.C. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 21 (2000) 1584-1590
2. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
3. Rost N.S., Wolf P.A., Kase C.S., Kelly-Hayes M., Silbershatz H., Massaro J.M., D'Agostino R.B., Franzblau C., and Wilson P.W. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 32 (2001) 2575-2579
4. Sesso H.D., Buring J.E., Rifai N., Blake G.J., Gaziano J.M., and Ridker P.M. C-reactive protein and the risk of developing hypertension. Jama 290 (2003) 2945-2951
5. Yin W.H., Chen J.W., Jen H.L., Chiang M.C., Huang W.P., Feng A.N., Young M.S., and Lin S.J. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J 147 (2004) 931-938
6. Chirinos J.A., Zambrano J.P., Chakko S., Schob A., Veerani A., Perez G.O., and Mendez A.J. Usefulness of C-reactive protein as an independent predictor of death in patients with ischemic cardiomyopathy. Am J Cardiol 95 (2005) 88-90
7. Owen N., Poulton T., Hay F.C., Mohamed-Ali V., and Steptoe A. Socioeconomic status, C-reactive protein, immune factors, and responses to acute mental stress. Brain Behav Immun 17 (2003) 286-295
8. Bertran N., Camps J., Fernandez-Ballart J., Arija V., Ferre N., Tous M., Simo D., Murphy M.M., Vilella E., and Joven J. Diet and lifestyle are associated with serum C-reactive protein concentrations in a population-based study. J Lab Clin Med 145 (2005) 41-46
9. Kondo N., Nomura M., Nakaya Y., Ito S., and Ohguro T. Association of inflammatory marker and highly sensitive C-reactive protein with aerobic exercise capacity, maximum oxygen uptake and insulin resistance in healthy middle-aged volunteers. Circ J 69 (2005) 452-457
10. Pankow J.S., Folsom A.R., Cushman M., Borecki I.B., Hopkins P.N., Eckfeldt J.H., and Tracy R.P. Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis 154 (2001) 681-689
11. MacGregor A.J., Gallimore J.R., Spector T.D., and Pepys M.B. Genetic effects on baseline values of C-reactive protein and serum amyloid a protein: a comparison of monozygotic and dizygotic twins. Clin Chem 50 (2004) 130-134
12. Wessel J., Moratorio G., Rao F., Mahata M., Zhang L., Greene W., Rana B.K., Kennedy B.P., Khandrika S., Huang P., Lillie E.O., Shih P.A., Smith D.W., Wen G., Hamilton B.A., Ziegler M.G., Witztum J.L., Schork N.J., Schmid-Schonbein G.W., and O'Connor D.T. C-reactive protein, an 'intermediate phenotype' for inflammation: human twin studies reveal heritability, association with blood pressure and the metabolic syndrome, and the influence of common polymorphism at catecholaminergic/beta-adrenergic pathway loci. J Hypertens 25 (2007) 329-343
13. Carlson C.S., Aldred S.F., Lee P.K., Tracy R.P., Schwartz S.M., Rieder M., Liu K., Williams O.D., Iribarren C., Lewis E.C., Fornage M., Boerwinkle E., Gross M., Jaquish C., Nickerson D.A., Myers R.M., Siscovick D.S., and Reiner A.P. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet 77 (2005) 64-77
14. Kovacs A., Green F., Hansson L.O., Lundman P., Samnegard A., Boquist S., Ericsson C.G., Watkins H., Hamsten A., and Tornvall P. A novel common single nucleotide polymorphism in the promoter region of the C-reactive protein gene associated with the plasma concentration of C-reactive protein. Atherosclerosis 178 (2005) 193-198
15. Suk H.J., Ridker P.M., Cook N.R., and Zee R.Y. Relation of polymorphism within the C-reactive protein gene and plasma CRP levels. Atherosclerosis 178 (2005) 139-145
16. Szalai A.J., Wu J., Lange E.M., McCrory M.A., Langefeld C.D., Williams A., Zakharkin S.O., George V., Allison D.B., Cooper G.S., Xie F., Fan Z., Edberg J.C., and Kimberly R.P. Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level. J Mol Med 83 (2005) 440-447
17. Brull D.J., Serrano N., Zito F., Jones L., Montgomery H.E., Rumley A., Sharma P., Lowe G.D., World M.J., Humphries S.E., and Hingorani A.D. Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Arterioscler Thromb Vasc Biol 23 (2003) 2063-2069
18. D'Aiuto F., Casas J.P., Shah T., Humphries S.E., Hingorani A.D., and Tonetti M.S. C-reactive protein (+1444C>T) polymorphism influences CRP response following a moderate inflammatory stimulus. Atherosclerosis 179 (2005) 413-417
19. Marsik C., Sunder-Plassmann R., Jilma B., Kovar F.M., Mannhalter C., Wagner O., Rumpold H., and Endler G. The C-reactive protein (+)1444C/T alteration modulates the inflammation and coagulation response in human endotoxemia. Clin Chem 52 (2006) 1952-1957
20. Szalai A.J., McCrory M.A., Cooper G.S., Wu J., and Kimberly R.P. Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun 3 (2002) 14-19
21. Weiss D., Sorescu D., and Taylor W.R. Angiotensin II and atherosclerosis. Am J Cardiol 87 (2001) 25C-32C
22. Richey J.M., Ader M., Moore D., and Bergman R.N. Angiotensin II induces insulin resistance independent of changes in interstitial insulin. Am J Physiol 277 (1999) E920-926
23. Strawn W.B., and Ferrario C.M. Mechanisms linking angiotensin II and atherogenesis. Curr Opin Lipidol 13 (2002) 505-512
24. Ruef J., Browatzki M., Pfeiffer C.A., Schmidt J., and Kranzhofer R. Angiotensin II promotes the inflammatory response to CD40 ligation via TRAF-2. Vasc Med 12 (2007) 23-27
25. Cheng Z.J., Vapaatalo H., and Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit 11 (2005) RA194-RA205
26. Sato H., Akai Y., Iwano M., Kurumatani N., Kurioka H., Kubo A., Yamaguchi T., Fujimoto T., and Dohi K. Association of an insertion polymorphism of angiotensin-converting enzyme gene with the activity of systemic lupus erythematosus. Lupus 7 (1998) 530-534
27. Vasku V., Vasku A., Izakovicova Holla L., Tschoplova S., Kankova K., Benakova N., and Semradova V. Polymorphisms in inflammation genes (angiotensinogen, TAP1 and TNF-beta) in psoriasis. Arch Dermatol Res 292 (2000) 531-534
28. Fliser D., Buchholz K., and Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110 (2004) 1103-1107
29. de Vinuesa S.G., Goicoechea M., Kanter J., Puerta M., Cachofeiro V., Lahera V., Gomez-Campdera F., and Luno J. Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade. J Am Soc Nephrol 17 (2006) S206-S212
30. Amar J., Ruidavets J.B., Peyrieux J.C., Mallion J.M., Ferrieres J., Safar M.E., and Chamontin B. C-reactive protein elevation predicts pulse pressure reduction in hypertensive subjects. Hypertension 46 (2005) 151-155
31. Palmas W., Ma S., Psaty B., Goff Jr. D.C., Darwin C., and Barr R.G. Antihypertensive medications and C-reactive protein in the multi-ethnic study of atherosclerosis. Am J Hypertens 20 (2007) 233-241
32. Tiret L., Blanc H., Ruidavets J.B., Arveiler D., Luc G., Jeunemaitre X., Tichet J., Mallet C., Poirier O., Plouin P.F., and Cambien F. Gene polymorphisms of the renin-angiotensin system in relation to hypertension and parental history of myocardial infarction and stroke: the PEGASE study. Projet d'Etude des Genes de l'Hypertension Arterielle Severe a moderee Essentielle. J Hypertens 16 (1998) 37-44
33. Wierzbicki A.S., Lambert-Hammill M., Lumb P.J., and Crook M.A. Renin-angiotensin system polymorphisms and coronary events in familial hypercholesterolemia. Hypertension 36 (2000) 808-812
34. Bonnardeaux A., Davies E., Jeunemaitre X., Fery I., Charru A., Clauser E., Tiret L., Cambien F., Corvol P., and Soubrier F. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 24 (1994) 63-69
35. Wang W.Y., Zee R.Y., and Morris B.J. Association of angiotensin II type 1 receptor gene polymorphism with essential hypertension. Clin Genet 51 (1997) 31-34
36. Kainulainen K., Perola M., Terwilliger J., Kaprio J., Koskenvuo M., Syvanen A.C., Vartiainen E., Peltonen L., and Kontula K. Evidence for involvement of the type 1 angiotensin II receptor locus in essential hypertension. Hypertension 33 (1999) 844-849
37. Rosmond R., and Björntorp P. Psychiatric ill-health of women and its relationship to obesity and body fat distribution. Obes Res 6 (1998) 338-345
38. Henningsson S., Hakansson A., Westberg L., Baghaei F., Rosmond R., Holm G., Ekman A., Nissbrandt H., and Eriksson E. Interleukin-6 gene polymorphism -174G/C influences plasma lipid levels in women. Obesity 14 (Silver Spring 2006) 1868-1873
39. Olsson M., Annerbrink K., Westberg L., Melke J., Baghaei F., Rosmond R., Holm G., Andersch S., Allgulander C., and Eriksson E. Angiotensin-related genes in patients with panic disorder. Am J Med Genet B Neuropsychiatr Genet 127 (2004) 81-84
40. Castellano M., Muiesan M.L., Beschi M., Rizzoni D., Cinelli A., Salvetti M., Pasini G., Porteri E., Bettoni G., Zulli R., and Agabiti-Rosei E. Angiotensin II type 1 receptor A/C1166 polymorphism. Relationships with blood pressure and cardiovascular structure. Hypertension 28 (1996) 1076-1080
41. Dandona P., Dhindsa S., Ghanim H., and Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens 21 (2007) 20-27
42. Kranzhofer R., Browatzki M., Schmidt J., and Kubler W. Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes. Biochem Biophys Res Commun 257 (1999) 826-828
43. Suzuki Y., Ruiz-Ortega M., and Egido J. Angiotensin II: a double-edged sword in inflammation. J Nephrol 13 Suppl 3 (2000) S101-S110
44. Luft F.C. Proinflammatory effects of angiotensin II and endothelin: targets for progression of cardiovascular and renal diseases. Curr Opin Nephrol Hypertens 11 (2002) 59-66
45. Ruiz-Ortega M., Ruperez M., Lorenzo O., Esteban V., Blanco J., Mezzano S., and Egido J. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl (2002) 12-22
46. Sezer S., Uyar M., Akcay A., Arat Z., Kulah E., Ozdemir F.N., and Haberal M. Endothelial nitric oxide synthase and angiotensin II type 1 receptor gene polymorphisms can influence chronic inflammatory state in renal transplant patients. Transplant Proc 37 (2005) 776-778
47. Ridker P.M., Danielson E., Rifai N., and Glynn R.J. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension 48 (2006) 73-79
48. Lottermoser K., Vetter H., and Düsing R. Blood pressure-independent atherogenic and thromboembolic mechanisms of the renin-angiotensin-aldosterone system. J Clin Basic Cardiol 4 (2004) 89-91
49. Agachan B., Isbir T., Yilmaz H., and Akoglu E. Angiotensin converting enzyme I/D, angiotensinogen T174 M-M235T and angiotensin II type 1 receptor A1166C gene polymorphisms in Turkish hypertensive patients. Exp Mol Med 35 (2003) 545-549
50. Zhu S., and Meng Q.H. Association of angiotensin II type 1 receptor gene polymorphism with carotid atherosclerosis. Clin Chem Lab Med 44 (2006) 282-284
51. Abdi R., Tran T.B., Zee R., Brenner B.M., and Milford E.L. Angiotensin gene polymorphism as a determinant of posttransplantation renal dysfunction and hypertension. Transplantation 72 (2001) 726-729
52. Amant C., Hamon M., Bauters C., Richard F., Helbecque N., McFadden E.P., Escudero X., Lablanche J.M., Amouyel P., and Bertrand M.E. The angiotensin II type 1 receptor gene polymorphism is associated with coronary artery vasoconstriction. J Am Coll Cardiol 29 (1997) 486-490
53. van Geel P.P., Pinto Y.M., Voors A.A., Buikema H., Oosterga M., Crijns H.J., and van Gilst W.H. Angiotensin II type 1 receptor A1166C gene polymorphism is associated with an increased response to angiotensin II in human arteries. Hypertension 35 (2000) 717-721
54. Martin M.M., Buckenberger J.A., Jiang J., Malana G.E., Nuovo G.J., Chotani M., Feldman D.S., Schmittgen T.D., and Elton T.S. The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microrna-155 binding. J Biol Chem 282 (2007) 24262-24269
55. Abdollahi M.R., Gaunt T.R., Syddall H.E., Cooper C., Phillips D.I., Ye S., and Day I.N. Angiotensin II type I receptor gene polymorphism: anthropometric and metabolic syndrome traits. J Med Genet 42 (2005) 396-401
56. Akasaka H., Katsuya T., Saitoh S., Sugimoto K., Fu Y., Takagi S., Ohnishi H., Rakugi H., Ura N., Shimamoto K., and Ogihara T. Effects of angiotensin II type 1 receptor gene polymorphisms on insulin resistance in a Japanese general population: the Tanno-Sobetsu study. Hypertens Res 29 (2006) 961-967
57. Thomas G.N., Tomlinson B., Chan J.C., Sanderson J.E., Cockram C.S., and Critchley J.A. Renin-angiotensin system gene polymorphisms, blood pressure, dyslipidemia, and diabetes in Hong Kong Chinese: a significant association of tne ACE insertion/deletion polymorphism with type 2 diabetes. Diabetes Care 24 (2001) 356-361
58. Fortunato G., Fattoruso O., De Caterina M., Mancini A., Di Fiore R., Alfieri A., Tafuri D., and Buono P. RAS and MTHFR gene polymorphisms in a healthy exercise-trained population: association with the MTHFR (TT) genotype and a lower hemoglobin level. Int J Sports Med 28 (2007) 172-177
59. Miller D.T., Zee R.Y., Suk Danik J., Kozlowski P., Chasman D.I., Lazarus R., Cook N.R., Ridker P.M., and Kwiatkowski D.J. Association of common CRP gene variants with CRP levels and cardiovascular events. Ann Hum Genet 69 (2005) 623-638
60. Ladenvall C., Jood K., Blomstrand C., Nilsson S., Jern C., and Ladenvall P. Serum C-reactive protein concentration and genotype in relation to ischemic stroke subtype. Stroke 37 (2006) 2018-2023
61. Suk Danik J., Chasman D.I., Cannon C.P., Miller D.T., Zee R.Y.L., Kozlowski P., Kozlowski D.J., and Ridker P.M. Influence of genetic variation in the C-reactive protein gene on the inflammatory response during and after acute coronary ischemia. Annals of Human Genetics 70 (2006) 1-12
62. Casas J.P., Shah T., Cooper J., Hawe E., McMahon A.D., Gaffney D., Packard C.J., O'Reilly D.S., Juhan-Vague I., Yudkin J.S., Tremoli E., Margaglione M., Di Minno G., Hamsten A., Kooistra T., Stephens J.W., Hurel S.J., Livingstone S., Colhoun H.M., Miller G.J., et al. Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol 35 (2006) 922-931
63. Morita A., Nakayama T., and Soma M. Association study between C-reactive protein genes and ischemic stroke in Japanese subjects. Am J Hypertens 19 (2006) 593-600
64. Kushner I., Rzewnicki D., and Samols D. What does minor elevation of C-reactive protein signify?. Am J Med 119 166 (2006) e117-128
65. Vickers M.A., Green F.R., Terry C., Mayosi B.M., Julier C., Lathrop M., Ratcliffe P.J., Watkins H.C., and Keavney B. Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc Res 53 (2002) 1029-1034
66. Jeanmonod P., von Kanel R., Maly F.E., and Fischer J.E. Elevated plasma C-reactive protein in chronically distressed subjects who carry the A allele of the TNF-alpha -308 G/A polymorphism. Psychosom Med 66 (2004) 501-506
67. Zhang Y.Y., Gottardo L., Mlynarski W., Frazier W., Nolan D., Duffy J., Marescotti M.C., Gervino E.V., Johnstone M.T., Mantzoros C.S., Avogaro A., and Doria A. Genetic variability at the leptin receptor (LEPR) locus is a determinant of plasma fibrinogen and C-reactive protein levels. Atherosclerosis 191 (2007) 121-127